Literature DB >> 12525287

Therapeutic Options for Herpes Simplex Infections.

Eugene Au1, Stephen L. Sacks.   

Abstract

Herpes simplex viruses are responsible for a number of disease states in infected individuals. Capable of establishing latent infection, herpes simplex can reactivate, causing pain, discomfort, and psychosocial consequences. Because no cure is available, treatment modalities for herpes simplex infection are required, from both personal and public health standpoints. To date, therapy has centered around the use of antiviral drugs to control infection and suppress recurrences. To expand the scope of available treatments, efforts have focused on the development of vaccines against herpes simplex virus and new agents such as immune response modifiers. Recent data suggest that these new agents are promising in their therapeutic potential.

Entities:  

Year:  2003        PMID: 12525287     DOI: 10.1007/s11908-003-0061-3

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  44 in total

Review 1.  The management of herpes simplex virus infections.

Authors:  Kimberly A Yeung-Yue; Mathijs H Brentjens; Patricia C Lee; Stephen K Tyring
Journal:  Curr Opin Infect Dis       Date:  2002-04       Impact factor: 4.915

2.  The topical microbicide PRO 2000 protects against genital herpes infection in a mouse model.

Authors:  N Bourne; D I Bernstein; J Ireland; A J Sonderfan; A T Profy; L R Stanberry
Journal:  J Infect Dis       Date:  1999-07       Impact factor: 5.226

3.  Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection.

Authors:  Anna Wald; David Carrell; Michael Remington; Elizabeth Kexel; Judy Zeh; Lawrence Corey
Journal:  Clin Infect Dis       Date:  2002-02-20       Impact factor: 9.079

Review 4.  Herpes simplex virus infections.

Authors:  R J Whitley; B Roizman
Journal:  Lancet       Date:  2001-05-12       Impact factor: 79.321

5.  Treatment of recurrent herpes simplex labialis with oral acyclovir.

Authors:  S L Spruance; J C Stewart; N H Rowe; M B McKeough; G Wenerstrom; D J Freeman
Journal:  J Infect Dis       Date:  1990-02       Impact factor: 5.226

6.  Acyclovir suppression of frequently recurring genital herpes. Efficacy and diminishing need during successive years of treatment.

Authors:  S E Straus; K D Croen; M H Sawyer; A G Freifeld; J M Felser; J K Dale; H A Smith; C Hallahan; S N Lehrman
Journal:  JAMA       Date:  1988-10-21       Impact factor: 56.272

7.  Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection.

Authors:  G J Mertz; R Ashley; R L Burke; J Benedetti; C Critchlow; C C Jones; L Corey
Journal:  J Infect Dis       Date:  1990-04       Impact factor: 5.226

Review 8.  Immunomodulation as a treatment strategy for genital herpes: review of the evidence.

Authors:  R L Miller; M A Tomai; C J Harrison; D I Bernstein
Journal:  Int Immunopharmacol       Date:  2002-03       Impact factor: 4.932

9.  Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group.

Authors:  M Reitano; S Tyring; W Lang; C Thoming; A M Worm; S Borelli; L O Chambers; J M Robinson; L Corey
Journal:  J Infect Dis       Date:  1998-09       Impact factor: 5.226

10.  Oral acyclovir to suppress frequently recurrent herpes labialis. A double-blind, placebo-controlled trial.

Authors:  J F Rooney; S E Straus; M L Mannix; C R Wohlenberg; D W Alling; J A Dumois; A L Notkins
Journal:  Ann Intern Med       Date:  1993-02-15       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.